Cancer

Personalis MRD Test Shows Superior Sensitivity in Lung Cancer Trial

The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca's NeoADAURA study.

Cancer

Test Gains Medicare Coverage for Early-Stage Breast Cancer Recurrence Monitoring

Coverage marks a step in expanding access to ultra-sensitive molecular residual disease detection for breast cancer patients.

Cancer

Thyroid Cancer Diagnosis Redefined with AI-Powered Biomarker

A new study introduces a dynamic biomarker system to improve early risk detection in differentiated thyroid carcinoma (DTC).

SeekInClarity Offers Promise in Monitoring Cancer Treatment Response

Jul 3, 2025 | Lymphoma

A new prospective study in BMC Cancer shows that the blood-based multi-omics test SeekInClarity accurately predicts treatment outcomes.

Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnostics

Jul 3, 2025 | Cancer

Lunit has partnered with Microsoft to co-develop scalable, AI-powered healthcare solutions that enhance cancer detection.

HRD Testing Best Practices Issued by AMP

Jun 25, 2025 | Cancer

AMP has published consensus best practice recommendations to standardize HRD testing in clinical laboratories.

Test Predicts Which Patients Will Not Respond to Chemotherapy

Jun 23, 2025 | Cancer

Researchers have developed genomic biomarkers to predict cancer patients’ resistance to chemotherapy, enabling more personalized treatment.

Esophageal Precancer Testing Program Launched at Hoag

Jun 20, 2025 | Unknown Origin & Other Cancer Types

Lucid Diagnostics and Hoag have launched a comprehensive esophageal precancer screening program using the non-endoscopic EsoGuard DNA test.

CAP Updates 23 Cancer Protocols

Jun 19, 2025 | Cancer

CAP has updated 23 cancer protocols to align with the latest standards from AJCC and WHO, enhancing diagnostic precision and patient care.

AI ‘Fragle’ Method Makes Cancer Tracking More Efficient

Jun 18, 2025 | Cancer

Researchers have developed an AI blood test called Fragle to accurately and affordably track cancer treatment response and detect relapse.

Avantect Pancreatic Cancer Test Enters Patient Enrollment Phase

Jun 17, 2025 | Pancreatic

ClearNote Health and University Hospital Southampton have launched the SAFE-D study to evaluate the Avantect Pancreatic Cancer Test.

A Precision Oncology Approach Calls for Regular ESR1 Monitoring

Jun 17, 2025 | Breast

Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.

Quest Diagnostics to Develop MCaST Blood Test

Jun 11, 2025 | Cancer

Quest Diagnostics is partnering with MD Anderson Cancer Center to develop a lab-based blood test for cancer that uses protein biomarkers.

Collaboration Expanded to Accelerate Progress in MASH Diagnosis

Jun 11, 2025 | Unknown Origin & Other Cancer Types

Echosens and Boehringer Ingelheim have expanded their partnership to improve early detection, diagnosis, and care access for MASH.

Liquid Biopsy Launched at Florida Cancer Institute

Jun 11, 2025 | Cancer

Florida Cancer Specialists & Research Institute now offers liquid biopsy, a minimally invasive blood test that enhances cancer diagnosis.

Cancer Screenings Continue Years After Guidelines Change to Limit Unnecessary Tests

Jun 10, 2025 | Cancer

It can take over a decade for unnecessary cancer screenings to significantly decline after updated guidelines advise against them.

Colorectal Cancer Screening: Are Smartphones the Answer?

Jun 5, 2025 | Colorectal

A study found that colorectal cancer screening could be boosted by using a rapid, accurate app-read smartphone FIT.

Gastric Cancer Biomarkers Identified in New Study

Jun 5, 2025 | Unknown Origin & Other Cancer Types

A new research study identifies lncRNAs CBR3-AS1 and PCA3 as significantly overexpressed in gastric cancer tissues.

Category: Cancer

Cancer

Cancer

Cancer